Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission

2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission

US Patent 6828318 · Granted Dec 7, 2004

Estimated economic value: $187,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagoni2022
Bicyclic compounds and methods for their use in treating autism2021
Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagoni2020
Bicyclic compounds and methods for their use in treating autism spectrum disorde2020
Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagoni2020
Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagoni2018
Neuroprotective bicyclic compounds and methods for their use in treating autism 2018
Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagoni2017
Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate2017
Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagoni2016
Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid2015
Triazolo [4, 5-D] pyramidine derivatives and their use as purine receptor antago2015